The Yield Growth Corp.

10:36 AM EST - The Yield Growth Corp. : Majority owned subsidiary NeonMind Biosciences Inc. announced submission of an application to Health Canada for an exemption to use a controlled substance for scientific purposes, pursuant to Section 56(1) of the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (a "Section 56 Exemption") for NeonMind's planned preclinical trial using psilocybin. "We expect to receive the exemption within several months. Researchers at the Lab have previously successfully obtained Section 56 Exemptions for research involving controlled substances," said Penny White, CEO of NeonMind. "Obesity is an enormous problem in modern society, increasing incidence of disease and putting a significant strain on our healthcare systems. The treatment of obesity is shifting focus towards root causes of the problem. We are looking at the problem from a more holistic standpoint, and believe that psychedelics may have great potential to make a positive impact in this area." The Yield Growth Corp. shares C.BOSS are trading unchanged at $0.10.